Propanc Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPCB research report →
Price Chart
About the company
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development.
- CEO
- James Nathanielsz
- IPO
- 2012
- Employees
- 2
- HQ
- Camberwell, VIC, AU
Get TickerSpark's AI analysis on PPCB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.84M
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.18
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -239.60%
- ROIC
- -310.51%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,185,569
- Net Income
- $-18,862,710+68.0%
- EPS
- $-176.16+95.3%
- OCF Growth
- -1302.5%
- FCF Growth
- -1302.5%
- 52W High
- $315.00
- 52W Low
- $1.61
- 50D MA
- $3.77
- 200D MA
- $18.46
- Beta
- 3.33
- RSI (14)
- 29
- Avg Volume
- 188.66K
No earnings-call transcripts are available for PPCB yet.
- Free Float
- 66.9%
- Shares Outstanding
- 1.03M
- Float Shares
- 691.48K
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 5, 23 | ZELINGER JOSEF | other | 15,000,000 |
| Aug 17, 21 | Kenyon Julian Norman | other | 3,420,000 |
| Aug 17, 21 | Nathanielsz James Andrew | other | 5,928,000 |
| Aug 17, 21 | Nathanielsz James Andrew | other | 2,800,000 |
| Aug 17, 21 | ZELINGER JOSEF | other | 0 |
| Jun 24, 19 | Campiciano Carlo M | other | 0 |
| May 14, 19 | Kenyon Julian Norman | other | 9,750,000 |
| May 14, 19 | Kenyon Julian Norman | other | 9,750,000 |
| May 14, 19 | Nathanielsz James Andrew | other | 19,500,000 |
| May 14, 19 | Nathanielsz James Andrew | other | 19,500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PPCB coverage
Recent articles, reports, and earnings notes.
No research on PPCB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PPCB report →Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
globenewswire.com · Nov 2
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
globenewswire.com · Oct 30
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
globenewswire.com · Oct 28
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
globenewswire.com · Oct 26
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
globenewswire.com · Oct 22
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
globenewswire.com · Oct 22
Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
globenewswire.com · Oct 16
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
globenewswire.com · Oct 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.